AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Feb 5, 2024
32254_dirs_2024-02-05_3675c501-ea49-4b7a-9987-5cb56147a3b2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-02-02
Reporting Person: Jones David Scott (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-02 | Common Stock | M | 209.00 | $11.47 | Acquired | 38171.00 | Direct |
| 2024-02-02 | Common Stock | S | 209.00 | $28.49 | Disposed | 37962.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-02 | Stock Option (Right to Buy) | $11.47 | M | 209.00 | Disposed | 2031-11-01 | Common Stock (209.00) | Direct |
Footnotes
F1: The option to purchase vests and becomes exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7